Ha habido 50 transacciones internas recientes registradas para Arbutus Biopharma Corporation (ABUS), incluyendo 31 compras y 10 ventas. El total de compras internas fue valorado en $16.12M y el total de ventas internas en $528.88K.
Internos destacados con actividad reciente incluyen Androski Lindsay, Nguyen Tuan, Sawhney Roger. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — ABUS
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-02-02 |
Androski Lindsay |
President and CEO |
Concesión de RSU |
28,000 |
- |
- |
28,000 |
| 2026-02-02 |
Nguyen Tuan |
Chief Financial Officer |
Concesión de RSU |
73,500 |
- |
- |
73,500 |
| 2025-08-04 |
Sawhney Roger |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-08-04 |
Sawhney Roger |
Director |
Concesión de RSU |
157,600 |
$3.34 |
$526.38K |
157,600 |
| 2025-03-31 |
Nguyen Tuan |
Chief Financial Officer |
Concesión de RSU |
750,000 |
$3.50 |
$2.63M |
750,000 |
| 2025-03-31 |
Nguyen Tuan |
Chief Financial Officer |
Concesión de RSU |
750,000 |
$3.49 |
$2.62M |
750,000 |
| 2025-03-28 |
Nguyen Tuan |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-03-18 |
Beardsley Robert A |
Director |
Concesión de RSU |
157,600 |
$3.20 |
$504.32K |
157,600 |
| 2025-03-18 |
Androski Lindsay |
President and CEO |
Concesión de RSU |
310,422 |
$3.20 |
$993.35K |
310,422 |
| 2025-03-18 |
Hasija Anuj |
Director |
Concesión de RSU |
157,600 |
$3.20 |
$504.32K |
157,600 |
| 2025-02-24 |
Beardsley Robert A |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-02-24 |
Gline Matthew |
10 Percent Owner |
Desconocido |
- |
- |
- |
38,847,462 |
| 2025-02-24 |
Androski Lindsay |
President and CEO |
Desconocido |
- |
- |
- |
- |
| 2025-02-24 |
Hasija Anuj |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-02-24 |
Bishop Joseph E |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-02-14 |
Hastings David C |
Chief Financial Officer |
Concesión de RSU |
90,100 |
- |
- |
249,824 |
| 2025-02-14 |
Naftzger J. Christopher |
General Counsel and Cco |
Concesión de RSU |
54,300 |
- |
- |
140,544 |
| 2025-02-14 |
Mcelhaugh Michael J. |
Interim President & CEO |
Concesión de RSU |
718,800 |
$3.29 |
$2.36M |
718,800 |
| 2025-02-14 |
Sims Karen |
Chief Medical Officer |
Concesión de RSU |
49,300 |
- |
- |
155,494 |
| 2025-02-04 |
Hastings David C |
Chief Financial Officer |
Venta Informativa |
22,183 |
$3.28 |
$72.83K |
159,724 |
| 2025-02-04 |
Naftzger J. Christopher |
General Counsel and Cco |
Venta Informativa |
11,333 |
$3.28 |
$37.21K |
86,244 |
| 2025-02-04 |
Mcelhaugh Michael J. |
Interim President & CEO |
Venta Informativa |
23,790 |
$3.28 |
$78.1K |
1,481,003 |
| 2025-02-04 |
Sims Karen |
Chief Medical Officer |
Venta Informativa |
19,348 |
$3.28 |
$63.52K |
106,194 |
| 2024-08-14 |
Manchester Keith S |
Director |
Ejercicio de Opciones (Venta) |
54,915 |
$0.56 |
$30.75K |
- |
| 2024-05-23 |
Henriques Richard C Jr |
Director |
Concesión de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Burgess Daniel D |
Director |
Concesión de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Manchester Keith S |
Director |
Concesión de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Meyers James R |
Director |
Concesión de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Torti Frank |
Director |
Concesión de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Rewolinski Melissa |
Director |
Concesión de RSU |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-02-02 |
Hastings David C |
Chief Financial Officer |
Venta Informativa |
9,593 |
$2.31 |
$22.18K |
181,907 |
| 2024-02-02 |
Sofia Michael J. |
Chief Scientific Officer |
Venta Informativa |
9,982 |
$2.31 |
$23.08K |
1,485,121 |
| 2024-02-02 |
Mcelhaugh Michael J. |
Interim President & CEO |
Venta Informativa |
10,164 |
$2.31 |
$23.5K |
1,504,793 |
| 2024-02-02 |
Sims Karen |
Chief Medical Officer |
Venta Informativa |
4,358 |
$2.31 |
$10.08K |
125,542 |
| 2024-02-01 |
Hastings David C |
Chief Financial Officer |
Concesión de RSU |
112,500 |
- |
- |
191,500 |
| 2024-02-01 |
Naftzger J. Christopher |
General Counsel and Cco |
Concesión de RSU |
95,100 |
- |
- |
95,100 |
| 2024-02-01 |
Sofia Michael J. |
Chief Scientific Officer |
Concesión de RSU |
437,800 |
$2.40 |
$1.05M |
437,800 |
| 2024-02-01 |
Mcelhaugh Michael J. |
Interim President & CEO |
Concesión de RSU |
495,100 |
$2.40 |
$1.19M |
495,100 |
| 2024-02-01 |
Sims Karen |
Chief Medical Officer |
Concesión de RSU |
101,000 |
- |
- |
129,900 |
| 2023-07-12 |
Rewolinski Melissa |
Director |
Desconocido |
- |
- |
- |
- |
| 2023-07-12 |
Rewolinski Melissa |
Director |
Concesión de RSU |
110,000 |
$2.27 |
$249.7K |
110,000 |
| 2023-07-10 |
Naftzger J. Christopher |
Officer |
Desconocido |
- |
- |
- |
- |
| 2023-07-10 |
Naftzger J. Christopher |
General Counsel and Cco |
Concesión de RSU |
500,000 |
$2.26 |
$1.13M |
500,000 |
| 2023-07-10 |
Sims Karen |
Chief Medical Officer |
Disposición |
57,800 |
$2.90 |
$167.62K |
- |
| 2023-07-10 |
Sims Karen |
Chief Medical Officer |
Concesión de RSU |
153,640 |
$2.26 |
$347.23K |
153,640 |
| 2023-05-24 |
Henriques Richard C Jr |
Director |
Concesión de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Burgess Daniel D |
Director |
Concesión de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Manchester Keith S |
Director |
Concesión de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Meyers James R |
Director |
Concesión de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Torti Frank |
Director |
Concesión de RSU |
55,000 |
$2.56 |
$140.8K |
55,000 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
